This is interesting, up until now there's been research coming out of china on the GLP1 Receptor Agonist class of drugs (*-glutides, ozempic, wegovy, mounjaro, etc) -- I wonder if we're about to see a bunch of chinese formulations hit the market.
If China has this problem at large scale, they might move a bit faster than others to rectify the accessibility/price issue